Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo

BMC Biotechnology

Volumn 12, Issue , 2012, Pages

  Gómez Sebastián, Silvia ^a   Nuñez, Maria C ^a   Garaicoechea, Lorena ^b   Alvarado, Carmen ^a   Mozgovoj, Marina ^b   Lasa, Rodrigo ^a   Kahl, Alan ^b   Wigdorovitz, Andres ^b   Parreño, Viviana ^b   Escribano, José M ^c  

^a UNIVERSIDAD POLITÉCNICA DE MADRID   (Spain)

^b INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

^c INIA   (Spain)

Author keywords

Baculovirus; IBES technology; Insect; Neutralization; Rotavirus A; Single domain antibodies; Therapeutic molecule

Indexed keywords

BACULOVIRUS; INSECT; NEUTRALIZATION; ROTAVIRUSES; SINGLE DOMAINS; THERAPEUTIC MOLECULES;

DEVELOPING COUNTRIES; ESCHERICHIA COLI; MOLECULES; TECHNOLOGY;

ANTIBODIES;

BACULOVIRUS VECTOR; PROTEIN VP6; SINGLE DOMAIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTHROPOD LARVA; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MICROBIAL BIOMASS; MOUSE; NEWBORN; NONHUMAN; ROTAVIRUS; ROTAVIRUS A; ROTAVIRUS INFECTION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; GENE EXPRESSION; HUMANS; LARVA; MICE; MICE, INBRED BALB C; MOTHS; ROTAVIRUS; ROTAVIRUS INFECTIONS; SINGLE-DOMAIN ANTIBODIES;

BACTERIA (MICROORGANISMS); HEXAPODA; MAMMALIA; MIRIDAE; MUS; ROTAVIRUS; ROTAVIRUS A; TRICHOPLUSIA NI;

EID: 84865813499     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-12-59     Document Type: Article

References (39)

1. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007, 77(1):13-22. 10.1007/s00253-007-1142-2, 2039825, 17704915.
2. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363(6428):446-448. 10.1038/363446a0, 8502296.
3. Conrath K, Vincke C, Stijlemans B, Schymkowitz J, Decanniere K, Wyns L, Muyldermans S, Loris R. Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol 2005, 350(1):112-125. 10.1016/j.jmb.2005.04.050, 15913651.
4. De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, Muyldermans S, Wyns L. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci USA 2006, 103(12):4586-4591. 10.1073/pnas.0505379103, 1450215, 16537393.
5. Garaicoechea L, Olichon A, Marcoppido G, Wigdorovitz A, Mozgovoj M, Saif L, Surrey T, Parreno V. Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice. J Virol 2008, 82(19):9753-9764. 10.1128/JVI.00436-08, 2546978, 18632867.
6. Pant N, Hultberg A, Zhao Y, Svensson L, Pan-Hammarstrom Q, Johansen K, Pouwels PH, Ruggeri FM, Hermans P, Frenken L, et al. Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis 2006, 194(11):1580-1588. 10.1086/508747, 17083044.
7. van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, Bellamy K, Sarker SA, van der Logt CP, Svensson L, Verrips CT, et al. Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine 2006, 24(19):4130-4137. 10.1016/j.vaccine.2006.02.045, 16616802.
8. Light DW, Andrus JK, Warburton RN. Estimated research and development costs of rotavirus vaccines. Vaccine 2009, 27(47):6627-6633. 10.1016/j.vaccine.2009.07.077, 19665605.
9. Feng N, Lawton JA, Gilbert J, Kuklin N, Vo P, Prasad BV, Greenberg HB. Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. J Clin Invest 2002, 109(9):1203-1213. 150959, 11994409.
10. Fleming FE, Graham KL, Taniguchi K, Takada Y, Coulson BS. Rotavirus-neutralizing antibodies inhibit virus binding to integrins alpha 2 beta 1 and alpha 4 beta 1. Arch Virol 2007, 152(6):1087-1101. 10.1007/s00705-007-0937-x, 17318737.
11. Joosten V, Roelofs MS, van den Dries N, Goosen T, Verrips CT, van den Hondel CA, Lokman BC. Production of bifunctional proteins by Aspergillus awamori: llama variable heavy chain antibody fragment (V(HH)) R9 coupled to Arthromyces ramosus peroxidase (ARP). J Biotechnol 2005, 120(4):347-359. 10.1016/j.jbiotec.2005.06.034, 16169108.
12. Harmsen MM, van Solt CB, Fijten HP. Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation. Appl Microbiol Biotechnol 2009, 84(6):1087-1094. 10.1007/s00253-009-2029-1, 2755796, 19455325.
13. Barderas MG, Wigdorovitz A, Merelo F, Beitia F, Alonso C, Borca MV, Escribano JM. Serodiagnosis of African swine fever using the recombinant protein p30 expressed in insect larvae. J Virol Methods 2000, 89(1-2):129-136.
14. Ferrer F, Zoth SC, Calamante G, Taboga O. Induction of virus-neutralizing antibodies by immunization with Rachiplusia nu per os infected with a recombinant baculovirus expressing the E2 glycoprotein of bovine viral diarrhea virus. J Virol Methods 2007, 146(1-2):424-427.
15. Gomez-Sebastian S, Perez-Filgueira DM, Gomez-Casado E, Nunez MC, Sanchez-Ramos I, Tabares E, Escribano JM. DIVA diagnostic of Aujeszky's disease using an insect-derived virus glycoprotein E. J Virol Methods 2008, 153(1):29-35. 10.1016/j.jviromet.2008.06.017, 18638504.
16. Lopez MG, Peralta A, Berinstein A, Fondevila N, Carrillo E, Taboga O. High-level expression of recombinant 3AB1 non-structural protein from FMDV in insect larvae. J Virol Methods 2005, 124(1-2):221-224.
17. Perez-Filgueira DM, Gonzalez-Camacho F, Gallardo C, Resino-Talavan P, Blanco E, Gomez-Casado E, Alonso C, Escribano JM. Optimization and validation of recombinant serological tests for African Swine Fever diagnosis based on detection of the p30 protein produced in Trichoplusia ni larvae. J Clin Microbiol 2006, 44(9):3114-3121. 10.1128/JCM.00406-06, 1594705, 16954235.
18. Alonso-Padilla J, de Oya NJ, Blazquez AB, Escribano-Romero E, Escribano JM, Saiz JC. Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease. Vaccine 2011, 29(9):1830-1835. 10.1016/j.vaccine.2010.12.081, 21211580.
19. Chimeno Zoth S, Gomez E, Carballeda JM, Taboga O, Carrillo E, Berinstein A. Potential use of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus expressed in Rachiplusia nu larvae as an immunogen for chickens. Clin Vaccine Immunol 2009, 16(5):775-778. 10.1128/CVI.00432-08, 2681597, 19297615.
20. Gomez-Casado E, Gomez-Sebastian S, Nunez MC, Lasa-Covarrubias R, Martinez-Pulgarin S, Escribano JM. Insect larvae biofactories as a platform for influenza vaccine production. Protein Expr Purif 2011, 79(1):35-43. 10.1016/j.pep.2011.03.007, 21421054.
21. Hu YC, Yao K, Wu TY. Baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Rev Vaccines 2008, 7(3):363-371. 10.1586/14760584.7.3.363, 18393606.
22. Johansson BE, Price PM, Kilbourne ED. Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine 1995, 13(9):841-845. 10.1016/0264-410X(94)00071-T, 7483807.
23. Matsuoka H, Kobayashi J, Barker GC, Miura K, Chinzei Y, Miyajima S, Ishii A, Sinden RE. Induction of anti-malarial transmission blocking immunity with a recombinant ookinete surface antigen of Plasmodium berghei produced in silkworm larvae using the baculovirus expression vector system. Vaccine 1996, 14(2):120-126. 10.1016/0264-410X(95)00162-T, 8852407.
24. Molinari P, Peralta A, Taboga O. Production of rotavirus-like particles in Spodoptera frugiperda larvae. J Virol Methods 2008, 147(2):364-367. 10.1016/j.jviromet.2007.09.002, 17945356.
25. Pang AL, Hashimoto CN, Tam LQ, Meng ZQ, Hui GS, Ho WK. In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system. Infect Immun 2002, 70(6):2772-2779. 10.1128/IAI.70.6.2772-2779.2002, 127970, 12010962.
26. Perez-Filgueira DM, Resino-Talavan P, Cubillos C, Angulo I, Barderas MG, Barcena J, Escribano JM. Development of a low-cost, insect larvae-derived recombinant subunit vaccine against RHDV. Virology 2007, 364(2):422-430. 10.1016/j.virol.2007.03.016, 17434554.
27. Wu X, Yin Z, Cao C, Huang L, Lu X, Liu J, Cui W. Expression of human VEGF165 in silkworm (Bombyx mori L.) by using a recombinant baculovirus and its bioactivity assay. J Biotechnol 2004, 111(3):253-261. 10.1016/j.jbiotec.2004.04.016, 15246661.
28. Liu Y, DeCarolis N, Beek N. Protein production with recombinant baculoviruses in lepidopteran larvae. Methods Mol Biol 2007, 388:267-280. 10.1007/978-1-59745-457-5_13, 17951775.
29. Millan AF, Gomez-Sebastian S, Nunez MC, Veramendi J, Escribano JM. Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva. Protein Expr Purif 2010, 74(1):1-8. 10.1016/j.pep.2010.06.009, 20600940.
30. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009, 1(5):443-452. 10.4161/mabs.1.5.9448, 2759494, 20065641.
31. Medin JA, Hunt L, Gathy K, Evans RK, Coleman MS. Efficient, low-cost protein factories: expression of human adenosine deaminase in baculovirus-infected insect larvae. Proc Natl Acad Sci USA 1990, 87(7):2760-2764. 10.1073/pnas.87.7.2760, 53770, 2181448.
32. Chazarra S, Aznar-Cervantes S, Sanchez-del-Campo L, Cabezas-Herrera J, Xiaofeng W, Cenis JL, Rodriguez-Lopez JN. Purification and kinetic properties of human recombinant dihydrofolate reductase produced in Bombyx mori chrysalides. Appl Biochem Biotechnol 2010, 162(7):1834-1846. 10.1007/s12010-010-8961-9, 20393885.
33. Romero LV, Targovnik AM, Wolman FJ, Cascone O, Miranda MV. Rachiplusia nu larva as a biofactory to achieve high level expression of horseradish peroxidase. Biotechnol Lett 2011, 33(5):947-956. 10.1007/s10529-011-0540-9, 21287234.
34. Gil F, Perez-Filgueira M, Barderas MG, Pastor-Vargas C, Alonso C, Vivanco F, Escribano JM. Targeting antigens to an invariant epitope of the MHC Class II DR molecule potentiates the immune response to subunit vaccines. Virus Res 2011, 155(1):55-60. 10.1016/j.virusres.2010.08.022, 20817054.
35. Park EY, Ishikiriyama M, Nishina T, Kato T, Yagi H, Kato K, Ueda H. Human IgG1 expression in silkworm larval hemolymph using BmNPV bacmids and its N-linked glycan structure. J Biotechnol 2009, 139(1):108-114. 10.1016/j.jbiotec.2008.09.013, 18984019.
36. Stepanyuk GA, Xu H, Wu CK, Markova SV, Lee J, Vysotski ES, Wang BC. Expression, purification and characterization of the secreted luciferase of the copepod Metridia longa from Sf9 insect cells. Protein Expr Purif 2008, 61(2):142-148. 10.1016/j.pep.2008.05.013, 2577724, 18595733.
37. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 2009, 198(3):157-174. 10.1007/s00430-009-0116-7, 2714450, 19529959.
38. Sisk WP, Bradley JD, Leipold RJ, Stoltzfus AM, Ponce de Leon M, Hilf M, Peng C, Cohen GH, Eisenberg RJ. High-level expression and purification of secreted forms of herpes simplex virus type 1 glycoprotein gD synthesized by baculovirus-infected insect cells. J Virol 1994, 68(2):766-775. 236513, 8289380.
39. To TL, Ward LA, Yuan L, Saif LJ. Serum and intestinal isotype antibody responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J Gen Virol 1998, 79(Pt 11):2661-2672.